1. CT-04 Using the american college of rheumatology and systemic lupus international collaborating clinics criteria to measure disease severity in discoid lupus erythematosus. (31st August 2016) Authors: Presto, JK; Haber, JS; Werth, VP Journal: Lupus science & medicine Issue: Volume 3(2016)Supplement 1 Page Start: A39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PO.4.75 The anti-BDCA2 antibody biib059 improves joint and skin manifestations in patients with SLE and both active arthritis and rash. (27th September 2022) Authors: Van Vollenhoven, RF; Furie, RA; Kalunian, K; Werth, VP; Carroll, H; Huang, X; Musselli, C; Barbey, C; Franchimont, N Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PO.6.135 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and phase II study design in patients with SLE and/or CLE (WILLOW). (27th September 2022) Authors: Morand, EF; Werth, VP; Bender, A; Deshpande, A; Deshmukh, A; Vaidyanathan, B; Vazquez-Mateo, C; Przetak, M; Moreau, F; Khursheed, M; Roy, S; Pearson, DR Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study. (27th September 2022) Authors: Van Vollenhoven, R; Pike, M; Merrill, JT; Morand, E; Werth, VP; Hobar, C; Delev, N; Shah, V; Sharkey, B; Wegman, T; Catlett, I; Banerjee, S; Singhal, S Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. SAT0222 BIIB059, a monoclonal antibody targeting BDCA2, shows evidence of biological activity and early clinical proof of concept in subjects with active cutaneous le. (15th June 2017) Authors: Furie, R; Werth, VP; Merola, JF; Reynolds, TL; Stevenson, L; Wang, W; Smirnakis, K; Barbey, C; Musselli, C; Werneburg, B; Rabah, D; Franchimont, N Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 857 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. SAT0255 A randomized, placebo-controlled, double-blind, ascending-dose, safety study of CC-220 in subjects with systemic lupus erythematosus. (15th June 2017) Authors: Werth, VP; Furie, R; Korish, S; Weiswasser, M; Azaryan, A; Schafer, PH; Delev, N; Choi, S; Hough, D Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 870 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗